These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 20924363)
1. Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Sharp PS; Bye-a-Jee H; Wells DJ Mol Ther; 2011 Jan; 19(1):165-71. PubMed ID: 20924363 [TBL] [Abstract][Full Text] [Related]
2. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Malerba A; Thorogood FC; Dickson G; Graham IR Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709 [TBL] [Abstract][Full Text] [Related]
3. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results. van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725 [TBL] [Abstract][Full Text] [Related]
5. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998 [TBL] [Abstract][Full Text] [Related]
6. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting. Maruyama R; Yokota T Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217 [TBL] [Abstract][Full Text] [Related]
7. Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice. Vila MC; Novak JS; Benny Klimek M; Li N; Morales M; Fritz AG; Edwards K; Boehler JF; Hogarth MW; Kinder TB; Zhang A; Mazala D; Fiorillo AA; Douglas B; Chen YW; van den Anker J; Lu QL; Hathout Y; Hoffman EP; Partridge TA; Nagaraju K J Pathol; 2019 Jul; 248(3):339-351. PubMed ID: 30883742 [TBL] [Abstract][Full Text] [Related]
8. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy. Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660 [TBL] [Abstract][Full Text] [Related]
9. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice. Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046 [TBL] [Abstract][Full Text] [Related]
10. Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice. Lu-Nguyen NB; Jarmin SA; Saleh AF; Popplewell L; Gait MJ; Dickson G Mol Ther; 2015 Aug; 23(8):1341-1348. PubMed ID: 25959011 [TBL] [Abstract][Full Text] [Related]
11. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy. Kendall GC; Mokhonova EI; Moran M; Sejbuk NE; Wang DW; Silva O; Wang RT; Martinez L; Lu QL; Damoiseaux R; Spencer MJ; Nelson SF; Miceli MC Sci Transl Med; 2012 Dec; 4(164):164ra160. PubMed ID: 23241744 [TBL] [Abstract][Full Text] [Related]
12. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Steinhaus JP; Moulton HM; Iversen PL; Wilton SD Mol Ther; 2007 Sep; 15(9):1587-92. PubMed ID: 17579573 [TBL] [Abstract][Full Text] [Related]
13. Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy. Blain AM; Greally E; McClorey G; Manzano R; Betts CA; Godfrey C; O'Donovan L; Coursindel T; Gait MJ; Wood MJ; MacGowan GA; Straub VW PLoS One; 2018; 13(6):e0198897. PubMed ID: 29912990 [TBL] [Abstract][Full Text] [Related]
14. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient. Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540 [TBL] [Abstract][Full Text] [Related]
15. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Yin H; Lu Q; Wood M Mol Ther; 2008 Jan; 16(1):38-45. PubMed ID: 17968354 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates. Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197 [TBL] [Abstract][Full Text] [Related]
17. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression. Lee JJA; Saito T; Duddy W; Takeda S; Yokota T Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539 [TBL] [Abstract][Full Text] [Related]
18. Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy. Benny Klimek ME; Vila MC; Edwards K; Boehler J; Novak J; Zhang A; Van der Meulen J; Tatum K; Quinn J; Fiorillo A; Burki U; Straub V; Lu QL; Hathout Y; van Den Anker J; Partridge TA; Morales M; Hoffman E; Nagaraju K J Neuromuscul Dis; 2021; 8(s2):S369-S381. PubMed ID: 34569970 [TBL] [Abstract][Full Text] [Related]